- The Washington Times - Saturday, December 1, 2001

A Finksburg, Md., businessman was sentenced yesterday in federal court in Baltimore to 46 months in prison for his guilty plea to selling an aloe vera solution to critically ill patients.
The businessman, Allen J. Hoffman, 55, was ordered by U.S. District Judge William M. Nickerson to pay $222,506 in restitution to his victims and to serve one year of supervised release.
U.S. Attorney Thomas M. DiBiagio said Hoffman also was ordered to refrain from the sale, distribution or marketing of aloe vera and cesium chloride as a treatment for any human disease, and told he could not engage in any activity involving the treatment of patients for any physical or mental disease or condition.
Hoffman pleaded guilty Sept. 21 to two felony counts charging him with Federal Drug Administration violations for the introduction of an unapproved new drug into interstate commerce with the intent to defraud, in violation of the Federal Food, Drug and Cosmetic Act.
In February, Mr. Nickerson ordered Hoffman to stop selling the solution to patients; he also was told not to sell, promote, distribute or advertise any products containing aloe vera or cesium chloride for the treatment or prevention of AIDS, cancer or any other disease. The judge also ordered that the U.S. Food and Drug Administration be allowed to inspect the facilities of Hoffman's company, Astec Biologics of Hanover, Pa., to ensure compliance.
Mr. DiBiagio said Hoffman and another company he owned, T-Up Inc., originally were charged in a 22-count indictment in July 1999 in a conspiracy to commit violations of federal criminal laws in connection with the promotion, sale and distribution of an unapproved new drug for cancer and AIDS known as "T-UP."
The drug, purportedly a concentrated form of aloe vera, was administered intravenously to cancer patients. Hoffman's co-defendant, Donald L. MacNay, pleaded guilty to fraud and conspiracy charges in March 2000.
Jerry Seper

Sign up for Daily Newsletters

Copyright © 2019 The Washington Times, LLC. Click here for reprint permission.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.


Click to Read More and View Comments

Click to Hide